Lytix Biopharma

Equities

LYTIX

NO0010405780

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-03 am EDT			5-day change	1st Jan Change
5.86 ^NOK	0.00%		+2.45%	+20.58%

Apr. 25	Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	CI
Apr. 10	Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	MT

Lytix Biopharma : CEO Presentation and Q&A with Redeye AB

April 22, 2024 at 09:20 am EDT

Our CEO, Øystein Rekdal, gives an update on upcoming milestones including the Verrica Phase II readout expected in Q2 and the ongoing capital raise. The presentation can be found here.

Attachments

Original Link
Permalink

Disclaimer

Lytix Biopharma AS published this content on 22 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 April 2024 13:19:19 UTC.

Latest news about Lytix Biopharma

Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	Apr. 25	CI
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	Apr. 10	MT
Transcript : Lytix Biopharma AS, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy	Jan. 05	MT
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology	Dec. 11	CI
Transcript : Lytix Biopharma AS, Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Lytix Biopharma AS - Special Call	23-10-23
Lytix Biopharma AS Announces Research Council of Norway Approves Lytix?s Application for Up to NOK 14.3 Million of Non-Dilutive Financial Support from the Skattefunn	23-10-17	CI
Lytix Biopharma Secures NOK14.3 Million Research Grant for Skin Cancer Treatment	23-10-17	MT
Transcript : Lytix Biopharma AS, Q2 2023 Earnings Call, Aug 31, 2023	23-08-31
Lytix Biopharma AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Lytix Biopharma Completes Patient Enrollment for LTX-315 Trial	23-08-28	MT
Lytix Biopharma AS Completes Recruitment of 20 Patients in the ATLAS-IT-05 Trial	23-08-28	CI
Lytix Biopharma's Licensing Partner Verrica Pharmaceuticals Inc. Reports Interim Phase 2 Data with LTX-315	23-08-11	CI
Lytix Biopharma AS Announces Presentation of Interim Data from ATLAS-IT-05 Study at ESMO 2023	23-07-19	CI
Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Lytix Biopharma Elects New Chair	23-04-19	MT
Lytix Biopharma AS Appoints Marie Ann Roskrow as New Chairman of the Board	23-04-18	CI
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
Lytix Biopharma Expands Clinical Trial for Skin Cancer Drug to Spain, France, Norway	22-11-14	MT

Chart Lytix Biopharma

Duration

Period

More charts

Company Profile

Lytix Biopharma AS is a Norway-based company engaged in biotechnology. The Company is involved in development, marketing and sales of pharmaceutical and biotechnology products, as well as related activities. Lytix Biopharma AS developing cancer immunotherapies, an area within cancer therapy that is aimed at activating the patientâs immune system to fight cancer. Lytix Biopharma molecules kill cancer cells, including resistant cells, and expose their internal components to the immune system. This results in uptake of tumor antigens and activation of tumor antigen-presenting cells, thereby generating a broad and long-lasting systemic T-cell response that overcomes tumor heterogeneity. Lytix Biopharma molecules can work in a wide variety of cancer indications and settings, both as mono- and combination therapies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LYTIX BIOPHARMA	+20.58%	21.66M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research